---
id: FC-363
type: Flashcard
created: 2025-08-08 10:02:05.927791
tags:
- Flashcard
- question
- cardiovascular
topic: cardiovascular
answer: C
related_articles:
- title: Over 13.6 Years, Children With Hypertension Are Twice As Likely to Have Major
    Adverse Cardiovascular Events.
  path: 2024/2024-12-over-136-years-children-with-hypertension-are-twice-as-likel.md
  similarity: 0.438
  link: '[[2024/2024-12-over-136-years-children-with-hypertension-are-twice-as-likel|Over
    13.6 Years, Children With Hypertension Are Twice As Likely to Have Major Adverse
    Cardiovascular Events.]]'
- title: Over 13.6 Years, Children With Hypertension Are Twice As Likely to Have Major
    Adverse Cardiovascular Events.
  path: 2024/2024-12-over-13-6-years-children-with-hypertension-are-twice-as-like.md
  similarity: 0.438
  link: '[[2024/2024-12-over-13-6-years-children-with-hypertension-are-twice-as-like|Over
    13.6 Years, Children With Hypertension Are Twice As Likely to Have Major Adverse
    Cardiovascular Events.]]'
- title: Large Increases in the Risk of Cardiovascular Events Following COVID-19 Infection
    That Required Hospitalization.
  path: 2022/2022-08-large-increases-in-the-risk-of-cardiovascular-events-followi.md
  similarity: 0.429
  link: '[[2022/2022-08-large-increases-in-the-risk-of-cardiovascular-events-followi|Large
    Increases in the Risk of Cardiovascular Events Following COVID-19 Infection That
    Required Hospitalization.]]'
- title: SGLT-2 Inhibitors Reduce Cardiovascular Mortality, but Benefit Is Modest,
    Even in Patients With Established Heart Disease.
  path: 2025/2025-01-sglt-2-inhibitors-reduce-cardiovascular-mortality-but-benefi.md
  similarity: 0.429
  link: '[[2025/2025-01-sglt-2-inhibitors-reduce-cardiovascular-mortality-but-benefi|SGLT-2
    Inhibitors Reduce Cardiovascular Mortality, but Benefit Is Modest, Even in Patients
    With Established Heart Disease.]]'
- title: PREVENT Equations for Assessing Cardiovascular Risk.
  path: 2024/2024-09-prevent-equations-for-assessing-cardiovascular-risk.md
  similarity: 0.429
  link: '[[2024/2024-09-prevent-equations-for-assessing-cardiovascular-risk|PREVENT
    Equations for Assessing Cardiovascular Risk.]]'
topics:
- Cardiology
- Emergency Medicine
- Infectious Disease
- Pediatrics
- Pulmonology
related_articles_2023_2025:
- title: editorial cardiovascular disparities south asian people
  path: 2024/07/2024-07-editorial-cardiovascular-disparities-south-asian-people.md
  similarity: 0.307
  link: '[[2024/07/2024-07-editorial-cardiovascular-disparities-south-asian-people|editorial
    cardiovascular disparities south asian people]]'
last_updated: '2025-08-10T20:25:13.856551'
---

# Flashcard FC-363

## Question

Inwhich one of the followingcasesispalivizumabrecommendedforprophylaxisagainstrespiratory syncytialvirus(RSV)? Achildtwoyearsofagewithaneuromusculardisorder. Achild15 monthsofagewithcongenitalheartdisease. Achild11 monthsofagewhowasbornat28 weeksofgestation. Achildthreeyearsofagewhoisimmunocompromised. @ Back

## Answer

**C**

## Explanation

Palivizumabisamonoclonalantibodygivenmonthlyduring RSVseasontochildrenathighriskofsevere infection;ithasbeenshowntopreventhospitalizations. High-riskconditionsincludebeingyoungerthan 12 monthsandhavingbeenbornatlessthan29 weeksofgestation,youngerthan12 monthswith hemodynamicallysignificantcongenitalheartdisease,youngerthan12 monthswithacongenital airway/pulmonaryabnormalityorneuromusculardisorderthatimpairsthechildsabilitytoclear secretions,andbeingyoungerthan24 monthswithanimmunocompromisingcondition. e

## References

- AAFPQuestion Bank-Pythonsimplecapture.
- whowasbornat28 weeksofgestation.
- whoisimmunocompromised.

